Le Lézard
Classified in: Health
Subject: PLW

Sytheon Granted 2 New US Patents on Isosorbide Diesters for Treating Atopic Dermatitis, Seeking Exclusive Partner to Bring to Market


PARSIPPANY, N.J., Dec. 13, 2023 /PRNewswire/ -- Sytheon is thrilled to announce that its new turnkey product for treating Atopic Dermatitis (eczema) has further patent protection ? and is actively seeking an exclusive partner to bring it to the OTC dermatological market.

Sytheon is thrilled to announce that its new turnkey product for treating eczema has further patent protection.

There is currently an unmet need for a sustainable, safe, and cost-effective product for those with mild to moderate Atopic Dermatitis (AD). Sytheon has a turnkey product, ActSES®, with solid science, patent protection, and clinical validation by UC-Davis, CA dermatologists ? and a new clinical study on children underway.

Market Opportunity for Atopic Dermatitis (AD)
Topical therapies are a mainstay treatment for AD, particularly for children or those with mild-to-moderate disease who may not qualify for systemic medications. The complexity of chronic AD is increased by the interplay of skin barrier dysfunction and immune dysregulation, resulting in the perpetuation of AD signs and symptoms.

ActSES®, a unique synergistic combination product of Isosorbide di-(linoleate/oleate) (Hydra Synol® IDL) + Isosorbide di-caprylate (Hydra Synol® DOI), has been developed by Sytheon to serve this unmet need. The effects of topically applied ActSES® are not limited to barrier repair but synergistically inhibit inflammatory cascades that amplify pruritus and cutaneous eruption.

For ActSES®, Sytheon has obtained two new US patents 11,753,414 (method) & 11,753,415 (composition), entitled "Composition and Methods for Treating Atopic Dermatitis." Sytheon has two earlier US Patents (10,597,402 & 11,312,725), which disclose "compositions and methods for restoring epidermal integrity and function and treating dermatol­ogical diseases."

Sytheon is actively looking for an exclusive partnership with the right organization to bring this turnkey product to the OTC dermatological market. To inquire, please send us a message here.
This news piece is also featured on SpecialChem and HAPPI.

About Sytheon
Sytheon is an innovative research-focused company committed to developing high-performance active ingredients for the personal care industry. Inspired by nature, all of Sytheon's ingredients have been scientifically and clinically validated to improve the health and beauty of the skin.
Visit our website: www.sytheonltd.com

SOURCE Sytheon Ltd.


These press releases may also interest you

7 mai 2024
Kirin Holdings Company, Limited (Kirin Holdings)(TOKYO:2503) and National Institute of Infectious Diseases (NIID) are jointly conducting studies to investigate the protective efficacy of L. lactis strain Plasma [postbiotic] (LC-Plasma) immunization...

7 mai 2024
Since 2019, NSG BioLabs has been a leader in co-working lab spaces in Singapore, and has nurtured over 40 biotech companies, of which the startups have achieved nearly US$400 million funding in total alongside significant business milestonesNSG...

7 mai 2024
Today, The Kids Mental Health Foundation (KMHF) hosted a panel alongside the Mental Health Storytelling, which is housed at the USC Annenberg Inclusion Initiative, in New York City. The...

7 mai 2024
The Board of Juno Pharmaceuticals Corporation is excited to announce the appointment of Jean-Guy Goulet as Chief Executive Officer (CEO). An executive with over 35 years of experience in the pharmaceutical industry, overseeing activities in Canada...

7 mai 2024
Mexico's pharmaceutical and personal care industry is undergoing significant changes with the strategic moves announced by Genomma Lab International, S.A.B. de C.V. (B.M.V.: LABB) regarding its agreement to redeem capital in Marzam. The...

7 mai 2024
Insert as subheadline: NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES The updated release reads: ZYUS LIFE SCIENCES CORPORATION TO PRESENT AT SIDOTI VIRTUAL INVESTOR CONFERENCE MAY 8-9 NOT FOR...



News published on and distributed by: